Omicure, incollaboration with the Centre Léon Bérard Comprehensive Cancer Center, announceat the ASCO 2023 conference their results to identify advanced lung cancer patients who could benefit most from immunotherapy.
For several years,OmiCure has been investing in the development of tumour profiling testing tools based on the sequencing and analysis of patients' DNA and RNA.
We already offer arange of products to meet these needs:
- The OmiCure® TLDxliquid biopsy test, a 591-gene DNA NGS (next-generation sequencing) panel, is a non-invasive tumour profiling test focused on key DNA alterations associated with tumours. It is ideal for non-invasive, tumour response monitoring and the identification of non-invasive treatment options when biopsy is not available.
- The OmiCure® TTDxsolid DNA panel, a 591-gene NGS test, enables rapid and accurate tumour profiling from tumour tissue.
However, while these products provide an initial response, they do not provide a complete answer to the problem. The future of tumour profiling lies in going even further inunderstanding how the author works, in particular by analysing the author's RNA. With this in mind, we are working on the development of various products such as :
-Onco KEM®- NGS RNASeq, a unique tumour profiling test that uses tumour gene expression profiles to identify a wider range of potentially beneficial treatments for patients without exploitable genetic alterations in the DNA.
And today, thanks to our collaboration with the exceptional team led by Saintigny Pierre at the prestigious Centre Léon Bérard, Lyon, France and ariana Pharma, we have made a remarkable discovery. The RNA expression of two genes, SOS2 and LIFR, have been shown to be powerfulbiomarkers that could potentially determine the timing of immunotherapy interventions. These discoveries could pave the way for highly personalised therapies for patients.
The abstract is available here: https://meetings.asco.org/abstracts-presentations/224666